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Abstract
Background: Postmortem studies of people who have successfully committed suicide and people with depression
have implicated the serotonin-1A (5-HT1A) receptor system in the pathophysiology of depression. Several molecular
imaging studies have investigated alterations in 5-HT1A receptors in patients with depression using positron
emission tomography and have reported conflicting results.
Methods: We performed a meta-analysis of studies investigating the relationship between depression and 5-HT1A
binding. We conducted a comprehensive search of Medline, Embase, ScienceDirect, Scopus and Springer databases
for relevant studies published between January 1999 and October 2015. The meta-analysis was conducted in
accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines.
Results: Ten studies were included, comprising 218 patients with depression and 261 healthy controls. The results
of these studies indicated a reduction in 5-HT1A receptors in mesiotemporal cortex, yielding a summary effect
estimate of -0.8 (95 % CI −1.36, −0.24). Smaller reductions were reported in 5-HT1A receptor binding in the
hippocampus, raphe nuclei, insular, anterior cingulate cortex and occipital cortex of people with depression. No
clear effect of depression on 5-HT1A receptors was detected in the amygdala.
Conclusions: Reduced 5-HT1A receptor binding was associated with the pathology of depression and predicted
altered serotonergic neurotransmission in various brain regions. These findings increase our understanding of the
neurophysiological processes underlying depression.
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Background
Depression is a chronic mental illness characterized by de-
pressed mood, anhedonia, irritability, concentration diffi-
culties, and abnormalities in appetite and sleep. It has a
lifetime prevalence of 10–15 % [21]. The classic biogenic
amine hypothesis of depression suggests that the disorder
is associated with a deficiency in several neurotransmit-
ters, including serotonin (5-hydroxytryptamine, 5-HT),
noradrenaline (NA), and acetylcholine (ACh) [3]. There is
increasing evidence that alterations in the brain serotoner-
gic system are involved in the pathophysiology of depres-
sion [13, 42]. It has been suggested that 5-HT receptor
dysfunction might contribute significantly to the develop-
ment of depression.
5-HT receptors are highly expressed in the human limbic
system, including the amygdala, hippocampus, thalamus,
putamen, anterior cingulate cortex and midbrain [37].
Among the 5-HT receptor types (5-HT1A, 5-HT1B, 5-
HT2A, and 5-HT4), 5-HT1A has generated much research
interest because of its involvement in recognition, learning
memory, and hippocampal neurogenesis, as well as its re-
sponse to antidepressant treatment [15, 36, 41]. Further-
more, 5-HT1A dysfunction often accompanies depression.
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Extensive rodent and human research suggests that 5-
HT1A dysregulation is highly sensitive to stress, i.e., in-
creased cortisol levels [9, 25].
A previous meta-analysis of molecular imaging studies
of depression reported a relationship between the dis-
order and serotonin transporters, which indicated al-
tered serotonergic availability in depression [14]. Recent
functional neuroimaging has pointed to widespread ab-
normalities in 5-HT1A binding in depression. Since
1991, abnormalities in 5-HT1A binding in patients with
depression have been investigated using positron emis-
sion tomography (PET) techniques under various scan-
ning conditions [1]. Several such studies have reported
decreased 5-HT1A binding in patients with depression
compared with healthy controls [34, 38]. However, other
studies have reported conflicting results or insufficient
evidence to confirm any relationship [20, 22, 23, 31].
While converging lines of evidence indicate that 5-
HT1A may contribute to the pathophysiology of depres-
sion, there is no consensus about the way 5-HT1A bind-
ing is altered in the condition. To address this
contention, we performed a meta-analysis of studies in-
vestigating the relationship between depression and 5-
HT1A binding. We hypothesized that at least some of
the discrepancies between studies would be explained by
our meta-analysis.
Methods
To ensure the quality of this meta-analysis, we followed
the proposal for conducting and reporting described in
‘Meta-analysis of Observational Studies in Epidemiology
(MOOSE)’ (Stroup DF 2000 [47]). The MOOSE check-
list is included in the Additional file 1.
Search strategy
Two reviewers (LW and CjZ), one postgraduate stu-
dent and one doctoral student, systematically searched
Medline, Embase, ScienceDirect, Scopus, and Springer
databases to identify relevant manuscripts published
between January 1999 and October 2015. Databases
were accessed via PubMed or directly via their
website.
We used subject and free-form search terms as follows
(the PubMed search string is provided as an example):
#1 depression [MeSH Terms] OR depress* OR bipolar
disorder OR affective disorders, psychotic OR major
depression;
#2 positron-Emission tomography [MeSH Terms] OR
pet OR tomography, emission-computed, single-photon
OR SPECT OR molecular imaging OR molecular
diagno*;
#3 receptor, serotonin, 5-HT1A[MeSH Terms] OR
serotonin 1A receptor;
#4 #1 AND #2 AND #3.
Study selection and data extraction
The inclusion criteria were: (1) original studies that
indexed 5-HT1A receptors in patients with depression
and healthy controls; (2) molecular imaging studies pub-
lished in English. We excluded: (1) subjects with neuro-
logical, severe somatic, psychotic, chronic stress or
affective disorders other than unipolar depression or bi-
polar depression; (2) reviews, comments, and case re-
ports; (3) overlapping or duplicated samples; (4) subjects
with depression accompanied by neuropsychiatric or
physical diseases; and (5) studies that included relatives
with significant symptoms. Where several contrasts or
tasks were present in the same study, we chose one task
to avoid including the sample twice.
The binding potential (BP) value of [11C]WAY-100635
was used as the primary outcome for the analysis. This
radioligand binds specifically to 5-HT1A and is widely
used in PET studies to measure 5-HT1A occupancy and
density in psychiatric patients [12]. Secondary outcomes
(listed by relevance to clinical and population character-
istics) included: diagnosis, symptoms severity, diagnosis
criteria for psychiatric diagnosis, rating tools, antidepres-
sant treatment, study and patient characteristics, mea-
surements performed, year of publication, population
characteristics, and type of tracer. Two reviewers (LW
and CjZ) extracted all data independently. Any disagree-
ment between reviewers was resolved by discussion.
Statistical methods
Statistical analyses were performed using RevMan ver-
sion 5.0.1 (The Cochrane Collaboration The Nordic
Cochrane Centre, Copenhagen, Denmark). The BP value
in given regions was weighted by standard mean differ-
ences (SMD) with a 95 % confidence interval (CI) for
each individual study. We used Q-tests with a signifi-
cance threshold of p < 0.05 (two-tailed) to evaluate the
SMD.
We assessed heterogeneity using a chi-squared Q-
statistic, and its magnitude was estimated using the in-
consistency index I2. I2 indicates the percentage of effect
size variance due to heterogeneity: I2 = 100 % × (Q-df)/Q
[16]. If between-study variance clearly made the assess-
ment of heterogeneity significant (p < 0.05), a random-
effects model was used to estimate the effects of major
depressive disorder (MDD) on 5-HT1A expression.
Publication bias is the tendency of small studies to re-
port large effect sizes. We assessed this parameter using
Begg’s funnel plots. The presence of bias was indicated
by asymmetrical plots. In addition, we conducted a sen-
sitivity analysis by excluding studies that might influence
pooled SMD.
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Results
Search results
We identified 408 potentially relevant studies, which
were managed in Endnote X7 (Thomas Reuters Scien-
tific, Philadelphia, PA, USA). After scanning each title
and abstract, 355 studies were excluded. Of the 53
remaining articles, 43 were further excluded: seven arti-
cles were systematic reviews; four articles did not report
5-HT1A binding measures; 15 articles were not con-
trolled clinical trials; ten articles included patients with
depression accompanied by neuropsychiatric or physical
diseases, or chronic stress or affective disorders other
than unipolar depression or bipolar depression; two arti-
cles did not supply adequate data; and five articles were
molecular imaging studies that likely overlapped with
another included study. Finally, ten studies remained for
inclusion in the meta-analysis ([4, 11, 18, 28, 32, 33, 35,
39, 43, 48]) (see Fig. 1). Three of the included studies
(marked with a “Δ” in Table 1) did not provide quantita-
tive data, and data were only available in a graphical for-
mat. For these studies, where we could not obtain
primary data by contacting the author, we used GetData
Graph Digitizer version 2.2 (GetData, Moscow, Russia)
to analyze the graphical data.
Table 1 shows data extracted from the ten included ar-
ticles, comprising 218 patients with depression and 261
healthy controls. The most frequently studied brain re-
gions in studies using PET to measure 5-HT1A binding
were the limbic system (cingulate cortex, amygdala,
hippocampus/parahippocampal), cortical regions (occipi-
tal cortex, temporal cortex, prefrontal cortex), raphe nu-
clei, and mesiotemporal cortex. In this meta-analysis, to
ensure reliability of findings, regions were included if
they were reported in a minimum of four studies. If sub-
regions within a structure (e.g. left mesiotemporal cortex
and right mesiotemporal cortex) were reported, the cor-
responding 5-HT1A BP values were combined and
averaged, according to the Cochrane Handbook for Sys-
tematic Reviews of Interventions version 5.0 [17].
Meta-analysis of 5-HT1A binding in depression
This meta-analysis focused on differences in 5-HT1A
binding between patients with depression and healthy
controls in six reported regions: hippocampus (HIP),
mesiotemporal cortex (MTC), anterior cingulate cortex
(ACN), occipital cortex (OCC), raphe nucleus (RN), and
insular cortex (INS).
Ten included studies investigated 5-HT1A binding in
MTC. The analysis yielded significantly lower binding in
people with depression, with an effect estimate of −0.8
(95 % CI −1.36, −0.24). Additionally, a moderate reduc-
tion of 5-HT1A binding in people with depression rela-
tive to healthy controls was detected in HIP: −0.29 (95 %
CI −0.51, −0.07), CAN: −0.57 (95 % CI −1.24, −0.09),
OCC: −0.35 (95 % CI −0.96, −0.04), RN: −0.60 (95 % CI
−1.17, −0.04) and INS: −0.79 (95 % CI −0.54, −0.05)
(Fig. 2).
Fig. 1 Flowchart of identification, screening and inclusion of eligible studies
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Table 1 Key characteristics of selected studies
1st author Publication
year









Wayne C. Drevets 1999 PET [11C]WAY-
100635
Cerebellum MDD, BPII HAM-17 22 ± 6.4 8 (4) 35.3 ± 13.5 12 (7) 35.8 ± 9.7 Drug free ≥2 week
Sargent P. Aa. 2000 PET [11C]WAY-
100635
Cerebellum MDD, BPII HAM-17 14.1 ± 194.9 18 (1) 36.4 ± 8.3 35 (3) 40 ± 34.5 Drug free ≥12
Z Bhagwagar 2004 PET [11C]WAY-
100635






Plasma MDD HAM-17 18.1 ± 2.7 17 (9) 70 ± 6.7 17 (13) 71.4 ±
5.9
Drug free ≥2 week
Jussi Hirvonen△ 2008 PET [11C]WAY-
100635








HAM-17 21 ± 4.3 7 (7) 33 ± 3.9 9 (9) 26.9 ± 7.9 7 patients rdrug
naïve
Ramin V. Parsey a△ 2006b PET [11C]WAY-
100635
Cerebellum MDD HAM-17 25.7 ± 7.08 43 (24) 38.2 ± 15 28 (7) 38.5 ±
29.3





Cerebellar white matter BPII HAM-17 18 ± 4.9 47 (27) 38.1 ±
14.7
32 (19) 38.4 ±
9.7
Drug free ≥2 week




MDD HAM-17 24.6 ± 5.3 51 (29) 37.3 ±
14.4
24 (17) 35 ± 13.3 Drug free ≥3
Allison C. Nugent 2013a PET [11C]WAY-
100635
Cerebellar white matte BPII MADRS 23 ± 10 33 ± 9.4 26 (19) 33 ± 9.5 Drug free ≥3 week
MDD major depressive disorder, BP bipolar depression, PET positron emission tomography, HAMD Hamilton depression scale, MADRS Montgomery and Asberg depression rating scale
aData from subgroups were combined and averaged (severity score, age, BP values)












In some studies, differences in 5-HT1A binding were
reported between patients with and without remission.
Therefore, we assumed that the severity of depressive
symptoms might influence 5-HT1A availability. However,
no relationship was found between depressive symptom
severity and 5-HT1A availability following subgroup ana-
lysis in the six regions mentioned above.
Sensitivity analysis
We hypothesized that depressive symptom severity,
small sample size (each arm containing fewer than 15
patients), and the chosen reference tissue might influ-
ence 5-HT1A availability measures (Additional files 1, 2
and 3). To test this hypothesis, we performed several
sensitivity analyses by deleting studies with each factor
respectively to assess which factors influenced the
results.
The results indicated that overall significance of the
SMD was altered after exclusion of two studies with
small sample sizes and one study with conflicting results
[32, 33, 43]. The results following exclusion of these
studies were as follows: MTC: −0.49 (95 % CI −0.71,
−0.27), p = 0.0001 for Q test, I2 = 27; HIP: −0.40 (95 %
CI −0.64, −0.19), p = 0.002 for Q test, I2 = 5; CAN: −0.41
(95 % CI −0.64, −0.19), p = 0.0004 for Q test, I2 = 36;
OCC: −0.50 (95 % CI −1.02, −0.02), p = 0.01 for Q test,
I2 = 68; RN: −0.21 (95 % CI −0.43, −0.02), p = 0.07 for Q
test, I2 = 44; and INS: −0.43 (95 % CI −0.86, −0.00), p =
0.009 for Q test, I2 = 66. These changes suggest that the
findings of the meta-analysis were strongly influenced by
these three studies.
Publication bias
A funnel plot was generated to explore publication bias
(Fig. 3). The results indicated that some publication bias
was present in the analyses of MTC, CAN, INS, OCC,
and RN. Publication bias may have been due to the lim-
ited number (n ≤ 10) of studies we included. There was
no evidence for publication bias in HIP.
Discussion
5-HT1A changes in depression
Our literature search yielded ten published studies of
5-HT1A receptor binding in depression, comprising
218 patients with depression and 261 healthy con-
trols. We found a mean group size of 22 patients and
26 controls per imaging study. Our meta-analysis
indicated significantly decreased 5-HT1A density in
MTC, and smaller reductions in 5-HT1A binding in
RN, INS, HIP, CAN and OCC in patients with
depression. The different PET imaging methods
employed in each study to measure 5-HT1A binding
Fig. 2 Forest plots showing the summary effect sizes of 5-HT1A binding in depression. HIP: hippocampus; MTC: mesiotemporal cortex; CAN: anterior
cingulate cortex; OCC: occipital cortex; RN: raphe nucleus; INS: insular cortex
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in high-affinity regions (i.e., RN, INS, and OCC) may
have contributed to high inter-study variability for
these particular regions.
Some previous studies have reported that 5-HT1A al-
terations in depression are influenced by antidepressant
medication, and remission and recovery status. In the 10
studies we included, patients were prescribed antidepres-
sants prior to study enrollment, but details of drug doses
and types were not reported. It was therefore difficult to
investigate whether antidepressant medication affected
5-HT1A availability during treatment in our meta-
analysis. We hypothesized that 5-HT1A binding would
be associated with depressive symptom severity. How-
ever, no relationship was found between the severity of
depressive symptoms and 5-HT1A availability in patients
with depression.
Fig. 3 Funnel plot analyzing publication bias for the summary effect sizes of 5-HT1A binding in depression. HIP: hippocampus; MTC: mesiotemporal
cortex; CAN: anterior cingulate cortex; OCC: occipital cortex; RN: raphe nucleus; INS: insular cortex
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Reduced 5-HT1A binding visualized with PET may
reflect changes in receptor density or affinity. Alterna-
tively, such reductions may reflect receptor down-
regulation, inter-activation, or blockage by endogen-
ous ligands (although [11C] WAY-100635 appears to
be insensitive to endogenous levels of serotonin; [6]).
In the current meta-analysis, we found significant re-
ductions in 5-HT1A in MTC (including amygdala).
This finding is consistent with previous postmortem
studies indicating lower 5-HT1A binding and mRNA
expression in MDD and bipolar disorder [24, 26, 27].
Postsynaptic 5-HT1A receptors exist in cortical inter-
neurons and pyramidal dendrites. These receptors
participate in feedback inhibition of 5-HT neuronal
activity and the modulation of cortical circuits [37].
Decreased 5-HT1A binding may act as a compensating
factor to improve postsynaptic serotonin reuptake
during a depressive episode. We speculate that de-
creased binding in the MTC of people with depres-
sion may impair the integration of 5-HT signaling in
cortico-mesiotemporal cortical circuits and disrupt
limbic input back to the cortex [2, 40]. Thus, the
reduction of 5-HT1A binding in depression found in
our meta-analysis may represent mesiotemporal 5-
HT1A-mediated dysregulation of cortical and limbic
structures.
We detected smaller differences in 5-HT1A binding be-
tween depression and healthy controls in HIP, RN, CAN,
and OCC. However, sensitivity analyses revealed stron-
ger trends toward reduced 5-HT1A binding. The HIP has
previously been shown to be structurally and function-
ally altered during depression [8, 29, 30]. However, the
data regarding 5-HT1A binding in OCC and RN merit
special attention for several reasons. First, there is evi-
dence that the RN contains many serotonergic cell bod-
ies that regulate 5-HT release and uptake. Collin et al.
[10] found that the level of expression of 5-HT trans-
porter mRNA was down-regulated in the rodent dorsal
raphe nucleus in obese behaviorally depressed ob/ob
mice. Decreased 5-HT1A autoreceptor binding was also
found in the dorsal raphe nucleus of people with depres-
sion who successfully committed suicide [7]. Moreover,
several studies have indicated that the OCC is involved
in depression, and γ-aminobutyric acid (GABA) concen-
trations in this region have been shown to be function-
ally altered in people with depression [5, 44]. These data
support the hypothesis that depression is associated
with reduced presynaptic serotonergic activity, which
leads to the down-regulation of postsynaptic 5-HT1A
sites. The results of the current meta-analysis suggest
that further imaging and animal studies are warranted
to investigate the specific role of 5-HT1A and seroto-
nergic dysfunction in the OCC and RN of patients
with depression.
Study heterogeneity
Study heterogeneity occurs when multiple studies inves-
tigating a particular effect are actually measuring differ-
ent effects. This may be caused by differences in
samples, interventions, statistical analyses, or study de-
signs, and may cause unreliability in meta-analyses. In
the current study, several factors may have caused high
heterogeneity, including the severity of depressive symp-
toms, small sample sizes, and the chosen reference tissue
for normalization in PET. Differences in PET scanning
protocols were also considered to be potentially import-
ant sources of variation between measurements [45].
Our results indicate that considerably more data are re-
quired for regions with high 5-HT1A abundance. More-
over, we found that the regions chosen for normalization
of specific binding to the radioactivity concentration in a
reference region differed between studies (plasma, cere-
bellum gray matter, cerebellum white matter, whole
cerebellum). These limitations, in combination with the
measurement error and substantial biological variability
in 5-HT1A, may have caused instability in group differ-
ences, reflecting an inherently problematic aspect of data
acquisition using PET. These findings highlight the ways
that specific technical differences in data collection and
analysis can produce conflicting or inconsistent results.
The development of a gold standard for arterial blood
with larger sample sizes in PET studies may provide a
solution that enables definitive conclusions about 5-
HT1A density in depression.
The association between the C(-1019)G polymorphism
in the promoter region of the 5-HT1A gene and depres-
sion may be another relevant factor. There is evidence
that higher expression of the G allele may increase the
risk of developing depression [19, 46, 49]. Therefore,
genetic variability may contribute to heterogeneity in
studies of 5-HT1A receptors in depression. It is possible
that the inter-study heterogeneity in SMD in the current
results was caused by genetic variation in 5-HT1A recep-
tors. However, we did not consider genetic variation in
our meta-analysis.
Study limitations
Several limitations should be considered in the interpret-
ation of our findings. First, the number of published
studies included was too small to exclude small study
bias (i.e., smaller studies contributing to larger effect
sizes). This finding indicates that future clinical molecu-
lar imaging studies should include larger sample sizes.
Second, some brain regions have been associated with
altered 5-HT1A binding but were not included in the
current analysis because of an insufficient number of
studies reporting data for these regions. Third, we sus-
pect that heterogeneity may result from genetic
variation, as well as differences in gender, depression
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severity, and treatment. However, we did not analyze
these factors, and did not obtain sufficiently detailed
data to allow such an analysis. Finally, we detected publi-
cation bias in this meta-analysis, possibly resulting from
the small number of studies included.
Conclusions
To our knowledge, this is the first meta-analysis of mo-
lecular imaging studies of 5-HT1A binding in depression.
It has been widely assumed that depression is associated
with changes in the 5-HT system. However, consistent
evidence from molecular imaging studies is limited. To
resolve this uncertainty, we performed a systematic re-
view and meta-analysis, which yielded ten molecular im-
aging studies of depression. Our meta-analysis showed a
decrease in 5-HT1A binding in MTC associated with de-
pression. Smaller reductions in 5-HT1A binding in HIP,
RN, CAN, OCC, and INS of patients with depression
were also found.
We conclude that individual molecular imaging stud-
ies have lacked sufficient statistical power to detect
serotonergic dysfunctions in depression. Furthermore,
potentially relevant factors, such as sample size, scan-
ning protocol, and genetic polymorphisms, should be
considered in future PET studies to further elucidate the
pathophysiological mechanisms underlying depression.
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